Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 10/20 | 0.61 |
| ▸ | PSMB1 | P20618 | 9/20 | 0.59 |
| ▸ | PSMB5 | P28074 | 9/20 | 0.59 |
| ▸ | PSMB9 | P28065 | 8/20 | 0.59 |
| ▸ | PSMB8 | P28062 | 8/20 | 0.59 |
| ▸ | PSMB10 | P40306 | 3/20 | 0.59 |
| ▸ | PSMB2 | P49721 | 3/20 | 0.59 |
| ▸ | KLK1 | P06870 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17268092 | 1.00 | KLKB1 (0.61) | KLKB1PSMB1PSMB5PSMB9PSMB8 | |
| SCHEMBL20136152 | 0.91 | CTSS (0.64) | — | |
| SCHEMBL14485661 | 0.91 | CTSS (0.64) | — | |
| SCHEMBL15900595 | 0.91 | PSMB1 (0.57) | KLKB1PSMB1PSMB5PSMB9PSMB8 | |
| SCHEMBL15900597 | 0.91 | PSMB1 (0.57) | KLKB1PSMB1PSMB5PSMB9PSMB8 | |
| SCHEMBL15901465 | 0.90 | KLKB1 (0.58) | KLKB1PSMB1PSMB5PSMB9PSMB8 | |
| SCHEMBL14485437 | 0.89 | KLKB1 (0.64) | KLKB1KLK1 | |
| SCHEMBL14485441 | 0.89 | KLKB1 (0.64) | KLKB1KLK1 | |
| SCHEMBL14485398 | 0.88 | KLKB1 (0.70) | KLKB1KLK1 | |
| SCHEMBL14485400 | 0.88 | KLKB1 (0.70) | KLKB1KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2729443-B3 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2020-02-12 | — | — | EP | disclosed |
| EP-2870137-B1 | POLYMORPHS OF N-[(R)-1-[(S)-1-(4-AMINOMETHYL-BENZYLCARBAMOYL)-2-PHENYL-ETHYLCARBAMOYL]-2-(4-ETHOXY-PHENYL)-ETHYL]-BENZAMIDE HYDROCHLORIDE | KALVISTA PHARMACEUTICALS LTD (GB) | 2018-05-16 | — | — | EP | disclosed |
| US-9512065-B2 | Polymorphs of N-[(R)-1-[(S)-1-(4-aminomethyl-benzylcarbamoyl)-2-phenyl-ethylcarbamoyl]-2-(4-ethoxy-phenyl)-ethyl]-benzamide hydrochloride | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-12-06 | — | — | US | disclosed |
| US-9234000-B2 | Benzylamine derivatives as inhibitors of plasma kallikrein | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-01-12 | — | — | US | disclosed |
| EP-2729443-B1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2015-11-25 | — | — | EP | disclosed |
| US-20150225450-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2015-08-13 | — | — | US | disclosed |
| US-20150191421-A1 | POLYMORPHS OF N-[(R)-1-[(S)-1-(4-AMINOMETHYL-BENZYLCARBAMOYL)-2-PHENYL-ETHYLCARBAMOYL]-2-(4-ETHOXY-PHENYL)-ETHYL]-BENZAMIDE HYDROCHLORIDE | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2015-07-09 | — | — | US | disclosed |
| US-9051249-B2 | Benzylamine derivatives as inhibitors of plasma kallikrein | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2015-06-09 | — | — | US | disclosed |
| US-20140213611-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191421-A1 | POLYMORPHS OF N-[(R)-1-[(S)-1-(4-AMINOMETHYL-BENZYLCARBAMOYL)-2-PHENYL-ETHYLCARBAMOYL]-2-(4-ETHOXY-PHENYL)-ETHYL]-BENZAMIDE HYDROCHLORIDE | SCN1A, SCN1B, BBC3 | KLKB1 3976/4885PSMB1 2484/4885PSMB5 2192/4885 |
| US-20150225450-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK1, BDKRB1 | KLKB1 1/4885PSMB1 1232/4885PSMB5 1505/4885 |
| US-20140213611-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK1, BDKRB1 | KLKB1 1/4885PSMB1 1232/4885PSMB5 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.